SCHEMBL2432602

SCHEMBL2432602

CN(C)/C=C/C(=O)c1ccc(-c2nc3ccc(Br)cc3s2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 7/20 0.59
RAB9A P51151 5/20 0.56
RECQL P46063 2/20 0.56
LMNA P02545 2/20 0.56
MAPT P10636 5/20 0.47
ALDH1A1 P00352 4/20 0.47
NPC1 O15118 4/20 0.47
KDM4E B2RXH2 2/20 0.47
NFKB1 P19838 2/20 0.47
NFKB2 Q00653 2/20 0.47
RELA Q04206 2/20 0.47
HPGD P15428 2/20 0.47
POLB P06746 2/20 0.47
MITF O75030 1/20 0.47
GAA P10253 1/20 0.47
GFER P55789 1/20 0.47
PAX8 Q06710 1/20 0.47
KLF5 Q13887 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2432605 1.00 APP (0.59) APPRAB9ARECQLLMNAMAPT
SCHEMBL2428611 0.80 APP (0.63) APPRAB9ARECQLLMNAMAPT
SCHEMBL31120302 0.75 APP (0.81) APPRAB9AMAPTALDH1A1NPC1
SCHEMBL2429085 0.75 MMP2 (0.65) RAB9ARECQLLMNA
SCHEMBL2429897 0.75 RAB9A (0.56) RAB9ARECQLLMNAMAPTALDH1A1
SCHEMBL2429095 0.75 MMP2 (0.65) RAB9ARECQLLMNA
SCHEMBL2429895 0.75 RAB9A (0.56) RAB9ARECQLLMNAMAPTALDH1A1
SCHEMBL2465837 0.75 APP (1.00) APPRAB9AMAPTNPC1KDM4E
SCHEMBL6513059 0.74 RAB9A (1.00) RAB9ARECQLLMNAMAPTALDH1A1
SCHEMBL1015798 0.74 RAB9A (1.00) RAB9ARECQLLMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1956013-B1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO LTD (JP) 2016-04-13 EP disclosed
US-8022075-B2 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition FUJIFILM RI PHARMA CO., LTD. (JP) 2011-09-20 US disclosed
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO., LTD. (JP) 2009-06-25 US disclosed
EP-1956013-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION Fujifilm RI Pharma Co., Ltd. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION APP, TTR, BACE1 APP 1/4885RAB9A 3111/4885RECQL 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.